HealthInvest Partners AB Grows Stock Position in Autolus Therapeutics plc (NASDAQ:AUTL)

HealthInvest Partners AB boosted its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 8.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 479,644 shares of the company’s stock after buying an additional 37,221 shares during the quarter. HealthInvest Partners AB’s holdings in Autolus Therapeutics were worth $1,060,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Dumont & Blake Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics during the 4th quarter worth about $35,000. Arkadios Wealth Advisors bought a new stake in Autolus Therapeutics in the fourth quarter worth about $47,000. Capstone Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics during the third quarter valued at approximately $51,000. Avanza Fonder AB bought a new position in shares of Autolus Therapeutics during the fourth quarter valued at approximately $75,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Autolus Therapeutics by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after buying an additional 14,959 shares during the period. Institutional investors own 72.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on AUTL. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, January 13th. Finally, The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $10.40.

Autolus Therapeutics Price Performance

Shares of NASDAQ:AUTL opened at $1.95 on Monday. The business’s 50 day moving average is $2.23 and its 200 day moving average is $3.18. The stock has a market cap of $518.88 million, a P/E ratio of -1.61 and a beta of 2.02. Autolus Therapeutics plc has a 52-week low of $1.87 and a 52-week high of $6.63.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.